G1 Therapeutics, Inc. (GTHX)

Market Cap	208.28M
Revenue (ttm)	82.51M
Net Income (ttm)	-47.97M
Shares Out	52.20M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	441,095
Open	3.850
Previous Close	3.860
Day's Range	3.840 - 4.045
52-Week Range	1.080 - 5.000
Beta	1.70
Analysts	Buy
Price Target	10.80 (+170.68%)
Earnings Date	May 1, 2024

About GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 2017
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: GTHX

Financial Performance

In 2023, GTHX's revenue was $82.51 million, an increase of 60.84% compared to the previous year's $51.30 million. Losses were -$47.97 million, -67.49% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price forecast is $10.8, which is an increase of 170.68% from the latest price.

Price Target

$10.8

(170.68% upside)

Analyst Consensus: Buy